Literature DB >> 11000474

Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain.

R Strohmeyer1, Y Shen, J Rogers.   

Abstract

Previous research on complement activation in the Alzheimer's disease (AD) brain has focused almost exclusively on the classical complement pathway. The alternative pathway represents another important arm for complement activation, converging with the classical cascade at the C5 cleavage step. Here, we show that mRNA for a critical alternative pathway component, factor B, is present in AD frontal cortex and that the factor D cleaved split products of factor B, Bb and Ba, are significantly increased, indicating alternative pathway activation. By contrast, the two major inhibitors of alternative pathway activation, factor H and factor I, are present at the level of mRNA and protein but are not significantly upregulated. Immunohistochemical analysis reveals significant positive staining in AD sections for all three components. Taken together with previous reports demonstrating alternative pathway activation by amyloid beta peptide, these findings suggest that conditions conducive to chronic alternative pathway activation may exist in the AD brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000474     DOI: 10.1016/s0169-328x(00)00149-2

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  33 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 2.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 3.  At the interface of sensory and motor dysfunctions and Alzheimer's disease.

Authors:  Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

Review 4.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

Review 5.  Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease.

Authors:  Pablo Iribarren; Ye Zhou; Jinyue Hu; Yingying Le; Ji Ming Wang
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  Complement factor H Y402H polymorphism is not associated with late-onset Alzheimer's disease.

Authors:  Gillian Hamilton; Petra Proitsi; Julie Williams; Michael O'Donovan; Michael Owen; John Powell; Simon Lovestone
Journal:  Neuromolecular Med       Date:  2007-09-22       Impact factor: 3.843

7.  Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues.

Authors:  Yuhsuke Ohmi; Orie Tajima; Yuki Ohkawa; Atsushi Mori; Yasuo Sugiura; Keiko Furukawa; Koichi Furukawa
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

Review 8.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

9.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

10.  Expression of complement system components during aging and amyloid deposition in APP transgenic mice.

Authors:  Julia Reichwald; Simone Danner; Karl-Heinz Wiederhold; Matthias Staufenbiel
Journal:  J Neuroinflammation       Date:  2009-11-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.